Clotting Factors and Antithrombin
Cigna coverage policy governing medical necessity and coding for clotting factor products and antithrombin (including Thrombate III, ATryn, and Obizur) for members of Cigna-administered health benefit plans.
Multiple Factor VIII products were removed from this policy and relocated to a new Hemophilia - Factor VIII Products (IP0618) policy.
Deleted HCPCS codes (list of J7*** and J72** codes) were removed from the policy coding section.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.